-

Genetix Biotherapeutics and the National Football League Alumni Association Announce Partnership to Increase Awareness for Sickle Cell Disease and Transformative Treatment Options

SOMERVILLE, Mass.--(BUSINESS WIRE)--Genetix Biotherapeutics Inc. and the National Football League Alumni Association today announced a partnership to launch a national awareness and education initiative for sickle cell disease. Through community engagement, the partnership will raise greater awareness of the difficulties of living with sickle cell disease, while helping individuals, families, and healthcare providers better understand available treatment options and support services. Many families are unaware that FDA-approved genetic medicines, including one-time transformative gene therapies, are available today and have proven to dramatically transform the lives of many people impacted by the disease.

Sickle cell disease is a severe rare disease and the most common inherited blood disorder in the U.S., affecting approximately 100,000 people and disproportionately impacting Black communities. Caused by a genetic mutation that leads to abnormal hemoglobin, sickle cell disease can result in serious lifelong complications including pain crises, stroke, organ damage, and reduced life expectancy, significantly impacting health and quality of life. While treatment has historically focused on symptom management, recent advances in genetic medicine have enabled the availability of one-time, transformative treatment options.

“For decades, Genetix has been committed to the sickle cell disease community, working alongside patients, families, advocates, and healthcare providers to advance care. Partnering with this community led to the development of an FDA-approved, one-time transformative treatment, making genetic medicine a reality for many people living with this debilitating disease,” said David Meek, Chief Executive Officer at Genetix. “Yet despite hundreds of patients now treated, the vast majority of eligible patients remain untreated, primarily due to lack of awareness that these treatment options are available today. We are excited that together with the National Football League Alumni Association, we will expand education and foster meaningful community conversations to improve the quality of life of those living with sickle cell disease.”

“The National Football League Alumni Association is proud to partner with Genetix to widen awareness and promote education on treatment options for people with sickle cell disease,” said Brad Edwards, Chief Executive Officer of the National Football League Alumni Association. “Many former NFL players and their families understand firsthand the devastating impact of this disease and the importance of ensuring patients and families have knowledge and access to available treatment options. By elevating personal stories with local community engagement from current and former players, we aim to raise awareness and connect patients and families with educational resources that support actionable next steps.”

About Genetix Biotherapeutics Inc.

Genetix Biotherapeutics Inc. is a privately held, commercial-stage biotechnology company pioneering the field of genetic medicine. With more than 30 years of experience, Genetix is dedicated to delivering transformative, one-time treatments for patients with rare disease, with a focus on hematology. The company has three FDA-approved gene addition cell therapies for sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy, designed to treat the underlying cause of disease with a single dose and deliver durable clinical benefit. Genetix is headquartered in Somerville, Massachusetts.

Website: www.genetixbiotx.com

About The National Football League Alumni Association

The National Football League Alumni Association is dedicated to serving, assisting, and promoting the welfare of former professional football players while supporting charitable, educational, and community-based initiatives across the United States. Through its network of former NFL players, cheerleaders, coaches, front-office executives and community leaders, the organization works to create meaningful impact in communities nationwide.

Contacts

For media inquiries:
Adrian Chaisson
adrian.chaisson@GenetixBioTx.com

Genetix Biotherapeutics Inc.


Release Versions

Contacts

For media inquiries:
Adrian Chaisson
adrian.chaisson@GenetixBioTx.com

More News From Genetix Biotherapeutics Inc.

Genetix Biotherapeutics and SPIMACO Announce Strategic Agreement to Commercialize and Manufacture LYFGENIA™ & ZYNTEGLO™ in Saudi Arabia and the Broader Middle East Region

SOMERVILLE, Mass.--(BUSINESS WIRE)--Genetix Biotherapeutics Inc. and the Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO) and its wholly owned subsidiary, SPIMACO Bio, today announced an exclusive collaboration and license agreement for the development, commercialization, and localized manufacturing of LYFGENIA™ and ZYNTEGLO™ in Saudi Arabia and across the broader Middle East. LYFGENIA and ZYNTEGLO are first-in-class, one-time gene addition cell therapies for the tre...

Genetix Announces 2025 Commercial Performance Results and Outlines 2026 Strategic Priorities

SOMERVILLE, Mass.--(BUSINESS WIRE)--Genetix Biotherapeutics Inc., the market leader in genetic therapies for hemoglobinopathies in the U.S., today announced commercial performance results from 2025 and outlined the company’s strategic priorities for 2026. “2025 was a groundbreaking year for our Company on many fronts. New leadership rebranded the Company to Genetix Biotherapeutics, delivered strong revenue growth, increased patient demand, and achieved its first ever profitable quarter,” said D...

Genetix Presents Recent Patient Experience Data from U.S. Commercial Gene Therapy Implementation at the 67th American Society of Hematology (ASH) Annual Meeting

SOMERVILLE, Mass.--(BUSINESS WIRE)--Genetix Biotherapeutics Inc. today announced real-world data from the commercial implementation of ZYNTEGLO™ and LYFGENIA™, first-in-class ex vivo gene addition therapies for the treatment of beta-thalassemia and sickle cell disease. With over 250 patients treated with these therapies, inclusive of clinical trials and commercial treatments, and long-term follow-up data beyond 10 years, Genetix has the most robust long-term dataset in ex vivo gene therapy for...
Back to Newsroom